Literature DB >> 19482888

The constitutive active/androstane receptor facilitates unique phenobarbital-induced expression changes of genes involved in key pathways in precancerous liver and liver tumors.

Jennifer M Phillips1, Lyle D Burgoon, Jay I Goodman.   

Abstract

Our overall goal is to elucidate progressive changes, in expression and methylation status, of genes which play key roles in phenobarbital (PB)-induced liver tumorigenesis, with an emphasis on their potential to affect signaling through critical pathways involved in the regulation of cell growth and differentiation. PB-elicited unique expression changes of genes, including some of those identified previously as exhibiting regions of altered DNA methylation, were discerned in precancerous liver tissue and/or individual liver tumors from susceptible constitutive active/androstane receptor (CAR) wild-type (WT) compared with resistant CAR knockout (KO) mice. Many of these function in crucial cancer-related processes, for example, angiogenesis, apoptosis, cell cycle, DNA methylation, Hedgehog signaling, invasion/metastasis, Notch signaling, and Wnt signaling. Furthermore, a subset of the uniquely altered genes contained CAR response elements (CAREs). This included Gadd45b, a coactivator of CAR and inhibitor of apoptosis, and two DNA methyltransferases (Dnmt1, Dnmt3a). The presence of CAREs in Dnmts suggests a potential direct link between PB and altered DNA methylation. The current data are juxtaposed with the effects of PB on DNA methylation and gene expression which occurred uniquely in liver tumor-prone B6C3F1 mice, as compared with the resistant C57BL/6, following 2 or 4 weeks of treatment. Collectively, these data reveal a comprehensive view of PB-elicited molecular alterations (i.e., changes in gene expression and DNA methylation) that can facilitate hepatocarcinogenesis. Notably, candidate genes for initial "fingerprints" of early and late stages of PB-induced tumorigenesis are proposed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19482888      PMCID: PMC2708600          DOI: 10.1093/toxsci/kfp108

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  52 in total

1.  Orphan nuclear receptor constitutive active/androstane receptor-mediated alterations in DNA methylation during phenobarbital promotion of liver tumorigenesis.

Authors:  Jennifer M Phillips; Yukio Yamamoto; Masahiko Negishi; Robert R Maronpot; Jay I Goodman
Journal:  Toxicol Sci       Date:  2006-12-16       Impact factor: 4.849

2.  Cancer biology. All in the stroma: cancer's Cosa Nostra.

Authors:  Jean Marx
Journal:  Science       Date:  2008-04-04       Impact factor: 47.728

3.  PPP1R16A, the membrane subunit of protein phosphatase 1beta, signals nuclear translocation of the nuclear receptor constitutive active/androstane receptor.

Authors:  Tatsuya Sueyoshi; Rick Moore; Junko Sugatani; Yonehiro Matsumura; Masahiko Negishi
Journal:  Mol Pharmacol       Date:  2008-01-17       Impact factor: 4.436

4.  Identification of genes that may play critical roles in phenobarbital (PB)-induced liver tumorigenesis due to altered DNA methylation.

Authors:  Jennifer M Phillips; Jay I Goodman
Journal:  Toxicol Sci       Date:  2008-03-20       Impact factor: 4.849

5.  Phenobarbital elicits unique, early changes in the expression of hepatic genes that affect critical pathways in tumor-prone B6C3F1 mice.

Authors:  Jennifer M Phillips; Lyle D Burgoon; Jay I Goodman
Journal:  Toxicol Sci       Date:  2009-03-06       Impact factor: 4.849

6.  The antiapoptotic factor growth arrest and DNA-damage-inducible 45 beta regulates the nuclear receptor constitutive active/androstane receptor-mediated transcription.

Authors:  Yukio Yamamoto; Masahiko Negishi
Journal:  Drug Metab Dispos       Date:  2008-03-24       Impact factor: 3.922

7.  A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals.

Authors:  Mark R Fielden; Richard Brennan; Jeremy Gollub
Journal:  Toxicol Sci       Date:  2007-06-08       Impact factor: 4.849

8.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

Review 9.  Epigenetic gene silencing in cancer: the DNA hypermethylome.

Authors:  Manel Esteller
Journal:  Hum Mol Genet       Date:  2007-04-15       Impact factor: 6.150

Review 10.  Epigenetic changes in cancer.

Authors:  Kirsten Grønbaek; Christoffer Hother; Peter A Jones
Journal:  APMIS       Date:  2007-10       Impact factor: 3.205

View more
  10 in total

1.  Widespread epigenetic changes to the enhancer landscape of mouse liver induced by a specific xenobiotic agonist ligand of the nuclear receptor CAR.

Authors:  Andy Rampersaud; Nicholas J Lodato; Aram Shin; David J Waxman
Journal:  Toxicol Sci       Date:  2019-06-24       Impact factor: 4.849

2.  Incorporation of an Epigenetic Evaluation into Safety Assessment: What we First Need to Know.

Authors:  Jay I Goodman
Journal:  Curr Opin Toxicol       Date:  2017-05-05

3.  Linking the aryl hydrocarbon receptor with altered DNA methylation patterns and developmentally induced aberrant antiviral CD8+ T cell responses.

Authors:  Bethany Winans; Anusha Nagari; Minho Chae; Christina M Post; Chia-I Ko; Alvaro Puga; W Lee Kraus; B Paige Lawrence
Journal:  J Immunol       Date:  2015-03-25       Impact factor: 5.422

Review 4.  Case examples of an evaluation of the human relevance of the pyrethroids/pyrethrins-induced liver tumours in rodents based on the mode of action.

Authors:  Tomoya Yamada
Journal:  Toxicol Res (Camb)       Date:  2018-01-16       Impact factor: 3.524

5.  Candidate genes responsible for early key events of phenobarbital-promoted mouse hepatocellular tumorigenesis based on differentiation of regulating genes between wild type mice and humanized chimeric mice.

Authors:  Ayako Ohara; Yasuhiko Takahashi; Miwa Kondo; Yu Okuda; Shuji Takeda; Masahiko Kushida; Kentaro Kobayashi; Kayo Sumida; Tomoya Yamada
Journal:  Toxicol Res (Camb)       Date:  2017-08-24       Impact factor: 3.524

6.  Phenobarbital mediates an epigenetic switch at the constitutive androstane receptor (CAR) target gene Cyp2b10 in the liver of B6C3F1 mice.

Authors:  Harri Lempiäinen; Arne Müller; Sarah Brasa; Soon-Siong Teo; Tim-Christoph Roloff; Laurent Morawiec; Natasa Zamurovic; Axel Vicart; Enrico Funhoff; Philippe Couttet; Dirk Schübeler; Olivier Grenet; Jennifer Marlowe; Jonathan Moggs; Rémi Terranova
Journal:  PLoS One       Date:  2011-03-24       Impact factor: 3.240

7.  Phenobarbital induces alterations in the proteome of hepatocytes and mesenchymal cells of rat livers.

Authors:  Philip Klepeisz; Sandra Sagmeister; Verena Haudek-Prinz; Melanie Pichlbauer; Bettina Grasl-Kraupp; Christopher Gerner
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

8.  Drug-induced chromatin accessibility changes associate with sensitivity to liver tumor promotion.

Authors:  Antonio Vitobello; Juliane Perner; Johanna Beil; Jiang Zhu; Alberto Del Río-Espínola; Laurent Morawiec; Magdalena Westphal; Valérie Dubost; Marc Altorfer; Ulrike Naumann; Arne Mueller; Karen Kapur; Mark Borowsky; Colin Henderson; C Roland Wolf; Michael Schwarz; Jonathan Moggs; Rémi Terranova
Journal:  Life Sci Alliance       Date:  2019-10-15

9.  Dynamic changes in 5-hydroxymethylation signatures underpin early and late events in drug exposed liver.

Authors:  John P Thomson; Jennifer M Hunter; Harri Lempiäinen; Arne Müller; Rémi Terranova; Jonathan G Moggs; Richard R Meehan
Journal:  Nucleic Acids Res       Date:  2013-04-17       Impact factor: 16.971

10.  Computational modeling identifies key gene regulatory interactions underlying phenobarbital-mediated tumor promotion.

Authors:  Raphaëlle Luisier; Elif B Unterberger; Jay I Goodman; Michael Schwarz; Jonathan Moggs; Rémi Terranova; Erik van Nimwegen
Journal:  Nucleic Acids Res       Date:  2014-01-23       Impact factor: 16.971

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.